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Abstract
Axial SpA (axSpA) can affect diverse elements of an individual’s life. The areas affected can be much more
wide-ranging than the historical medical model of SpA, causing increased disease activity (pain and
stiffness) and disability (reduced range of movement and physical function). A more holistic view of the
individual results in the realization that many other areas of life can be adversely affected by axSpA, from
the ability to work effectively and function socially, to effects on quality of life and the onset of worsening
fatigue or mood disturbance. A good understanding of these areas outside the medical model allows for
an improved understanding of the overall life impact of axSpA. This highlights the importance of under-
standing how to measure these elements of life using patient-reported outcome measures that can truly
reflect an individual’s experience of axSpA. These measures can then provide a better insight into the
risks and benefits of interventions and medications used to treat axSpA.
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Rheumatology key messages
. The impact of axial SpA is much wider than physical function, pain and disease activity.
. Axial SpA may affect work, mood, fatigue and quality of life.
. Interventions considered for axial SpA should include a spectrum from psychological counselling to biological.
Introduction
Important advances in the diagnosis and classification of
SpA over the past 10 years particularly include the dem-
onstration of spinal inflammation using MRI in the absence
of radiographic evidence of change [1, 2]. The diagnosis of
axial SpA (axSpA) reflects patients within a spectrum of
disease presentations and investigations and ranges from
those with radiographic sacroiliac changes (previously
referred to as AS) to those with only clinical features sug-
gesting axial inflammation. Patients with axSpA without
radiographic evidence of sacroiliitis can now be classified
as having non-radiographic axSpA, which does not
appear to differ significantly from radiographic axSpA
(synonymous with AS) in terms of the main clinical mani-
festations, disease activity, pain and effect of biologics
[35]. Although non-radiographic axSpA has less inflam-
mation (lower CRP levels and less spinal inflammation on
MRI) and less impairment in spinal mobility compared with
AS, the two ends of the spectrum are associated with a
similar burden in terms of physical function, mood disturb-
ance, work impact and quality of life impairment [6].
Before the introduction of the Assessment of
SpondyloArthritis international Society (ASAS) criteria,
the adult prevalence of AS was estimated to be between
0.1 and 1.4%. It varies with geographical region (reflecting
varying prevalence of HLA-B27), with the highest rates
found in northern Europeans and indigenous North
Americans [79]. European estimates include a preva-
lence of 0.9% in Germany [8] and 1.11.4% in northern
Norway [9], which are markedly higher than estimates in
non-Caucasian populations such as Turkey at 0.25% [10]
or China at 0.11% [11].
The more inclusive classification criteria will have a con-
siderable impact on the increasing prevalence of SpA, be-
cause many patients with previously unclassifiable axSpA
can now be identified as having SpA [1]. This has
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socioeconomic implications for the overall burden of dis-
ease. AxSpA occurs in young adults at the peak of their
productive lifespan [2] and is associated with a consider-
able burden in terms of restrictions in activities of daily
living [12, 13] and reduction in health-related quality of
life (HRQoL) [13], work productivity and rates of employ-
ment [7, 14, 15]. Because axSpA usually starts before
45 years of age, the effect of the disease on different as-
pects of life (career, family and social life) is of consider-
able duration.
Importance of reduction in work
productivity on individuals and society
Reduction in work productivity is an important component
of the indirect costs of SpA, which are typically calculated
in terms of absenteeism and presenteeism using the Work
Productivity and Activity Impairment Questionnaire in AS
[16]. Absenteeism is defined as the quantity of potentially
disease-related sick leave, whereas presenteeism is defined
as patient-reported reduced productivity at work [16].
In a UK study of 612 AS patients [15], employment rates
were 14% lower than the UK national average, with 39.5%
of patients of working age being unemployed, 44% of
whom related this to poor health. In a more recent
Italian study [17], axSpA employment rates were slightly
lower than in the general population (53% vs 58%), 14%
of patients reported axSpA-related discrimination at work
and the proportion of patients receiving disability benefits
was nearly five times higher than that in the general popu-
lation (34% vs 7.3%). However, extrapolation of data be-
tween AS and axSpA and from one country to another is
challenging because of local influencing factors such as
local unemployment/disability benefit systems [18].
A number of factors have been found to be associated
with work disability and loss of productivity at work.
Unemployment is associated with older age, social de-
privation, longer disease duration, functional impairment
and depression. Absenteeism is associated with worse
disease activity and depression, while presenteeism is
associated with a wider range of factors including older
age, worse disease activity, poorer physical function,
lower quality of life, anxiety, depression [15] and a sense
of helplessness [19]. Correlations between increased
signs and symptoms of disease and reduced work prod-
uctivity suggest that treatments aimed at improving help-
lessness, reducing anxiety/depression and controlling
disease activity could also reduce work disability and
loss of productivity [15, 19, 20].
Frequency of psychological symptoms in
axSpA and their impact on patients’
overall well-being
Psychological distress, including symptoms of depression
and anxiety, is an important factor to consider when
determining outcomes and quality of life in patients with
axSpA. Some studies have described the close associ-
ation between mood and measures of self-reported
disease activity, functional status, educational achieve-
ment, deprivation, pain and HRQoL in AS [2128].
Psychological distress is frequently reported in patients
with a variety of rheumatic disorders, more commonly
than in the general population [29]. The reported preva-
lence of depression and anxiety in axSpA is extremely
wide, varying between 9 and 56%, and 19 and 60%, re-
spectively [2128, 30]. Anxiety and depression scores
were reported in one study to be similar in AS and in
non-radiographic axSpA [24].
Although historically underevaluated because of low
numbers of women in studies, recent publications have
indicated that women with AS have more depression
[21] and anxiety [22] than men with the condition. As in
the general population, social deprivation may affect the
psychological state of individuals with axSpA [23].
Disease activity scores (including BASDAI and ASDAS-
CRP) significantly correlate with both anxiety and depres-
sion in AS [2426, 28], with one study also reporting ESR,
a laboratory measure of inflammation, as an independent
risk factor for higher anxiety scores [26]. In the one axSpA
study to date to examine the relationship between psy-
chological distress and disease activity, only depression
(not anxiety) appears to be related to disease activity [24].
Decreased physical function and AS-related restricted
range of movement also appear to detrimentally influence
mood [2426]. Both poor disease activity and physical
function are also associated with wider psychological
characteristics such as passive coping strategies and a
sense of helplessness [27, 28].
Fatigue
Health economic burden, a major component of which is
fatigue, increases steeply with increasing disease activity
[31]. Estimates suggest that up to 66% of patients with AS
are affected by fatigue [32], comparable to the rate in
other long-term inflammatory conditions such as RA
[33]. The complex, multi-dimensional nature of fatigue
associated with a range of rheumatological conditions
has been distinguished from normal everyday tiredness
by frequency, persistence, unpredictability and failure to
be resolved by rest [34, 35]. Growing acknowledgment of
the relative importance of AS fatigue [36] has fuelled inter-
est in its treatment and management [37, 38], and high-
lighted the need for accurate and credible assessment
[38].
Current international guidance for AS fatigue assess-
ment is limited to a single item, the global assessment
of severity (BASDAI question 1) [39]. The complex nature
of fatigue experienced in AS means that limited assess-
ment potentially fails to identify patients at risk of fatigue-
related impairment.
The fatigue related to the inflammatory elements of
axSpA may be detrimentally affected by the fatigue from
concurrent pain syndromes such as FM [40], which is
more common in patients with AS than in the general
population. In comparison with a population prevalence
of 24% [41], a Brazilian study [42] reported a prevalence
of FM of 15.0% in patients with AS. This is consistent with
vi30 https://academic.oup.com/rheumatology
Jonathan Packham
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
the observation of the high prevalence of FM in inflamma-
tory rheumatic diseases in general [41]. The presence of
FM alongside axSpA may influence patients’ perceptions
of pain, function and disease activity, and may distort re-
sponses to key patient-reported outcome measures such
as BASDAI and the BASFI.
HRQoL
HRQoL is a broad, multi-dimensional concept that usually
includes subjective evaluations of both positive and nega-
tive aspects of life. It may be defined as the ‘net conse-
quence of a disease and its treatment on a patient’s
perception of his or her ability to live a useful and fulfilling
life’ [43]. It is challenging to measure because quality of
life has a different meaning for nearly every individual and
every disease state. Although health is one of the import-
ant domains of overall quality of life, there are other
equally important aspects of life that can be affected by
illness, such as family life, social support, body image,
ability to work, housing, spirituality and socioeconomic
status [43].
Despite these challenges, HRQoL questions have
become an important component of public health surveil-
lance and are generally considered valid indicators of
unmet needs and intervention outcomes. The efficient
and cost-effective management of any disease requires
competing treatment regimens to be evaluated for their
ability to both control disease activity and improve the
quality of life of patients.
AS often has a significant impact upon an individual’s
HRQoL [44]; the magnitude of this is at least equivalent to
that seen in patients with other chronic conditions such as
diabetes, arthritis and hypertension [45]. Traditional meth-
ods of evaluation—with their focus on the locomotor
system, measures of impairment and disease activ-
ity—will inevitably fail to describe the extensive multi-di-
mensional issues associated with axSpA disease.
Given the typical age at onset of the disease and the
subsequent progression towards disability with, historic-
ally, few therapeutic alternatives, it is perhaps not surpris-
ing that patients with axSpA have had such diminished
HRQoL. As spinal mobility is progressively lost, or pain
levels escalate, difficulty in performing simple physical
routines places a huge burden on these patients that ex-
tends beyond the physical hardship and compromises the
patient’s social and psychological function. Reductions in
HRQoL are most pronounced in the more physical and
disease activity domains, but are also clearly evident in
the psychosocial domains: axSpA leads to changes in
mood or personality, low self-esteem, stigma of disease
and worry about the future, and adversely affects social
life and relationships with friends and family [46]. For ex-
ample, uncontrolled axSpA disease may threaten the abil-
ity of a young adult to remain in employment and hence
support their family both financially and emotionally [47]. It
may affect them physically, for instance by limiting the
amount of sport they can participate in and directly influ-
encing self-perceptions of success in achieving a trad-
itional gender role. Consequently, their ability to fulfil
their role as a partner, a parent and a member of society
is challenged.
Overall health and functioning
Recently, ASAS introduced the first AS-specific health
index (ASAS HI), which can be used to measure overall
functioning and health [48]. The index contains 17 patient-
rated items covering the whole range of International
Classification of Functioning, Disability and Health cate-
gories, including pain, emotional functions, sleep, sexual
functions, mobility, self-care and community life. Patients
are asked to respond ‘agree’ or ‘do not agree’ with a
statement in each category, resulting in a score from 0
to 17. Unlike the symptom-specific instruments described
above, ASAS HI captures whether problems are present in
different categories of functioning rather than the subject-
ive experience of those problems [48].
Therapy for AS
There is good evidence that treatment with many of the
licensed biologic therapies is associated with significant
improvements in all aspects of HRQoL, from disease ac-
tivity, pain and physical functioning to work stability, pa-
tients’ psychological health and global quality of life
[4954]. These important changes in the clinical manage-
ment of axSpA have resulted in the widespread use of
biologic therapies.
People with aggressive disease are offered such treat-
ments more commonly, and at an earlier stage in the dis-
ease course [55]. The evidence is clear that short-term
benefits can be considerable. However, there are also
short-term risks (e.g. increased vulnerability to infection),
and the long-term consequences of these treatments
(e.g. theoretical risk of malignancy) remain uncertain
[56]. This is of particular concern in AS/axSpA: those
who are offered biologics are often in relatively early adult-
hood, at a point when their disease is at its most severe
and their wider lives are characterized by change and un-
certainty, when they are confronted with a decision that
may have profound long-term consequences.
Shared decision-making
Healthcare professionals play an important role as
providers of information and advice for patients [57, 58].
However, treatment decisions are also influenced by inter-
actions with people outside the healthcare team [59, 60].
In considering lay influence, the research literature
focuses substantially on the significant other, often a
long-term partner or spouse [61, 62]. Given that people
are committing to a partner much later in life than in the
past [63, 64] and a growing proportion of younger adults
do not have a significant other, focusing exclusively on
this relationship as a source of influence or support for
decision-making is problematic.
Being clear who is involved in helping patients make
healthcare decisions is important in order to ensure every-
one involved has appropriate information. The healthcare
https://academic.oup.com/rheumatology vi31
Optimizing holistic outcomes for axSpA patients
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/suppl_6/vi29/5184858 by Keele U
niversity user on 15 January 2019
team needs to foresee challenges and pre-empt potential
problems in order to tailor care and information effectively
to patients’ needs.
Conclusion
The wide-ranging impact of AS/axSpA on the individual
means that a holistic approach should be taken. Treating
the inflammation and presuming everything else will im-
prove is overly simplistic and runs the real risk of missing
disease impact on major areas of life, with the potential to
prevent patients managing and living successfully with
their disease. Adopting a patient-centred approach and
ensuring that the impact of AS/axSpA is considered
across the physical, psychological, vocational and social
spectrum, rather than maintaining a narrow focus on dis-
ease activity, should enhance care and achieve real-life
improvements for patients.
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